On March 17, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (ADC) portfolio at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"For the first time, we will present comprehensive preclinical proof-of-concept for our three ADC programs, HWK-007, HWK-016 and HWK-206," said David Dornan, PhD, Chief Scientific Officer of Whitehawk Therapeutics. "These data will highlight the optimized ADC design features aimed at delivering a differentiated ADC profile with the goal of improving outcomes for cancer patients."
Whitehawk’s comprehensive preclinical abstracts demonstrate a potential best-in-class therapeutic index among next-generation TOP1i-based ADCs. These data showed high potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, Whitehawk’s ADCs demonstrated a high tolerability with a highest non-severely toxic dose (HNSTD) of 60 mg/kg. Underpinning these results is one of the lowest reported free payload in circulation, driven by Whitehawk’s proprietary "carbon-bridge cysteine repairing" linker-payload.
Presentation details:
HWK-016 – MUC16-Targeted ADC (Minisymposium Oral Presentation)
Title: Preclinical assessment of HWK-016, a next-generation, MUC16-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: David Dornan, PhD, CSO, Whitehawk Therapeutics
Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms
Presentation Number: 1324
Date & Time: April 19, 2026, 3:00 – 5:00 pm
HWK-007 – PTK7-Targeted ADC (Poster Presentation)
Title: Preclinical assessment of HWK-007, a next-generation, PTK7-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: Kathleen S. Keegan, PhD, VP of R&D, Whitehawk Therapeutics
Section 12: Antibody-Drug Conjugates and Linker Engineering 3
Poster Number: 4439
Date & Time: April 21, 2026, 9:00 am – 12:00 pm
HWK-206 – SEZ6-Targeted ADC (Poster Presentation)
Title: Preclinical assessment of HWK-206, a next-generation, biparatopic, SEZ6-targeting ADC with novel bioconjugation and linker–payload technology
Presenter: Kathleen S. Keegan, PhD, VP of R&D, Whitehawk Therapeutics
Section 12: Antibody-Drug Conjugates and Linker Engineering 3
Poster Number: 4440
Date & Time: April 21, 2026, 9:00 am – 12:00 pm
These abstracts are currently available on the AACR (Free AACR Whitepaper) 2026 meeting website, and the presentation and posters will be accessible on the Presentations page of the Investors & News section of the Company’s website at www.whitehawktx.com.
(Press release, Whitehawk Therapeutics, MAR 17, 2026, View Source [SID1234663635])